AMPA Receptor Modulation for Enhancing Plasticity and Treating Neuropathology
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Effects of Chronic Systemic Low-Impact Ampakine Treatment On
Biomedicine & Pharmacotherapy 105 (2018) 540–544 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Effects of chronic systemic low-impact ampakine treatment on neurotrophin T expression in rat brain ⁎ Daniel P. Radin , Steven Johnson, Richard Purcell, Arnold S. Lippa RespireRx Pharmaceuticals, Inc., 126 Valley Road, Glen Rock, NJ, 07452, United States ARTICLE INFO ABSTRACT Keywords: Neurotrophin dysregulation has been implicated in a large number of neurodegenerative and neuropsychiatric Ampakine diseases. Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating BDNF their expression are greatly needed. It has been demonstrated previously that neurotrophins are up regulated in Cognitive enhancement response to increases in brain activity. Therefore, molecules that act as cognitive enhancers may provide a LTP clinical means of up regulating neurotrophin expression. Ampakines are a class of molecules that act as positive Neurotrophin allosteric modulators of AMPA-type glutamate receptors. Currently, they are being developed to prevent opioid- NGF induced respiratory depression without sacrificing the analgesic properties of the opioids. In addition, these molecules increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats. In the current study, we examined whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition. Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions. Notable increases in NGF were ob- served in the dentate gyrus and piriform cortex while notable BDNF increases were observed in basolateral and lateral nuclei of the amygdala. -
Architecture Moléculaire Des Récepteurs NMDA : Arrangement Tétramérique Et Interfaces Entre Sous-Unités Morgane Riou
Architecture moléculaire des récepteurs NMDA : Arrangement tétramérique et interfaces entre sous-unités Morgane Riou To cite this version: Morgane Riou. Architecture moléculaire des récepteurs NMDA : Arrangement tétramérique et inter- faces entre sous-unités. Neurosciences [q-bio.NC]. Université Pierre et Marie Curie - Paris VI, 2014. Français. NNT : 2014PA066081. tel-01020863 HAL Id: tel-01020863 https://tel.archives-ouvertes.fr/tel-01020863 Submitted on 8 Jul 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THESE DE DOCTORAT De l’Université Pierre et Marie Curie - Paris VI Ecole Doctorale Cerveau Cognition Comportement ARCHITECTURE MOLECULAIRE DES RECEPTEURS NMDA : ARRANGEMENT TETRAMERIQUE ET INTERFACES ENTRE SOUS-UNITES Présentée par : Morgane RIOU Institut de Biologie de l' Ecole Normale Supérieure (IBENS) CNRS UMR8197, INSERM U1024 Ecole Normale Supérieure, 46 rue d’Ulm, 75005 Paris Direction Générale de l' Armement Soutenue le 28 février 2014 devant le jury composé de : Pr. Germain TRUGNAN Président Dr. David PERRAIS Rapporteur Dr. Pierre -
Oncolytic Properties of Ampakines in Vitro DANIEL P
ANTICANCER RESEARCH 38 : 265-269 (2018) doi:10.21873/anticanres.12217 Oncolytic Properties of Ampakines In Vitro DANIEL P. RADIN, RICHARD PURCELL and ARNOLD S. LIPPA RespireRx Pharmaceuticals, Inc., Glen Rock, NJ, U.S.A. Abstract. Background/Aim: The 5-year survival rate of crucial for the consolidation of learning and memory (1, 2). glioblastoma (GBM) is ~10%, demonstrating that a new Over the past two decades, considerable strides have been therapeutic modality for this cancer is desperately needed. made in understanding AMPAR pharmacology, kinetics and Complicating the search for such a modality is that most large physiology by employing positive allosteric modulators molecules cannot pass through the blood brain barrier, so (PAMs) to delineate their function (3). For convenience, the molecules demonstrating efficacy in vitro may not be useful in term ampakines has been used to describe various classes of vivo because they never reach the brain. Recently, the selective drugs that act as PAM. serotonin reuptake inhibitor (SSRI) fluoxetine (FLX) was Ampakines are further categorized as Class I ampakines, identified as an effective agent in targeting GBM in vitro and also known as high-impact ampakines, and Class II in vivo by agonizing AMPA-glutamate receptors (AMPARs), ampakines, also known as low-impact ampakines (3). Class eliciting massive calcium influx and mitochondrial calcium I or high-impact ampakines increase AMPAR agonist overload and apoptosis. Materials and Methods: In the current binding affinity by stabilizing the channel open confirmation study, we used a colorimetric cell viability assay to determine of the AMPAR, thereby offsetting desensitization, and if we could enhance the oncolytic effect of FLX in vitro by pre- enhancing AMPAergic steady-state currents up to 100-fold treating cells with an AMPAR-positive allosteric modulator (4). -
Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al. -
Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
Pharmaceuticals 2014, 7, 29-45; doi:10.3390/ph7010029 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction? Lucas R. Watterson 1,* and M. Foster Olive 1,2 1 Department of Psychology, Behavioral Neuroscience Area, Arizona State University, Tempe, AZ 85287, USA 2 Interdisciplinary Graduate Program in Neuroscience, Arizona State University, Tempe, AZ 85287, USA * Author to whom correspondence should be addressed; E-Mail:[email protected]; Tel.: +1-480-965-2573. Received: 28 October 2013; in revised form: 13 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013 Abstract: Positive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between various cortical and subcortical regions, and some of these compounds increase the production and release of brain-derived neurotrophic factor (BDNF) in an activity-dependent manner. Through these mechanisms, AMPA PAMs have shown promise as broad spectrum pharmacotherapeutics in preclinical and clinical studies for various neurodegenerative and psychiatric disorders. In recent years, a small collection of preclinical animal studies has also shown that AMPA PAMs may have potential as pharmacotherapeutic adjuncts to extinction-based or cue-exposure therapies for the treatment of drug addiction. The present paper will review this preclinical literature, discuss novel data collected in our laboratory, and recommend future research directions for the possible development of AMPA PAMs as anti-addiction medications. -
Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors
The Journal of Neuroscience, September 28, 2005 • 25(39):9027–9036 • 9027 Cellular/Molecular Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors Rongsheng Jin,1 Suzanne Clark,4 Autumn M. Weeks,4 Joshua T. Dudman,2 Eric Gouaux,1,3 and Kathryn M. Partin4 1Department of Biochemistry and Molecular Biophysics, 2Center for Neurobiology and Behavior, and 3Howard Hughes Medical Institute, Columbia University, New York, New York 10032, and 4Department of Biomedical Sciences, Division of Neuroscience, Colorado State University, Fort Collins, Colorado 80523 Ligand-gated ion channels involved in the modulation of synaptic strength are the AMPA, kainate, and NMDA glutamate receptors. Small molecules that potentiate AMPA receptor currents relieve cognitive deficits caused by neurodegenerative diseases such as Alzheimer’s disease and show promise in the treatment of depression. Previously, there has been limited understanding of the molecular mechanism of action for AMPA receptor potentiators. Here we present cocrystal structures of the glutamate receptor GluR2 S1S2 ligand-binding domain in complex with aniracetam [1-(4-methoxybenzoyl)-2-pyrrolidinone] or CX614 (pyrrolidino-1,3-oxazino benzo-1,4-dioxan-10- one), two AMPA receptor potentiators that preferentially slow AMPA receptor deactivation. Both potentiators bind within the dimer interface of the nondesensitized receptor at a common site located on the twofold axis of molecular symmetry. Importantly, the poten- tiator binding site is adjacent to the “hinge” in the ligand-binding core “clamshell” that undergoes conformational rearrangement after glutamatebinding.Usingrapidsolutionexchange,patch-clampelectrophysiologyexperiments,weshowthatpointmutationsofresidues that interact with potentiators in the cocrystal disrupt potentiator function. We suggest that the potentiators slow deactivation by stabilizing the clamshell in its closed-cleft, glutamate-bound conformation. -
Enhancement of Ampakine-Induced
(19) & (11) EP 1 715 863 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/445 (2006.01) A61K 31/40 (2006.01) 09.05.2012 Bulletin 2012/19 A61K 31/4525 (2006.01) A61K 45/06 (2006.01) (21) Application number: 05712023.0 (86) International application number: PCT/US2005/002372 (22) Date of filing: 26.01.2005 (87) International publication number: WO 2005/072345 (11.08.2005 Gazette 2005/32) (54) ENHANCEMENT OF AMPAKINE-INDUCED FACILITATION OF SYNAPTIC RESPONSES BY CHOLINESTERASE INHIBITORS VERBESSERUNG DER DURCH AMPAKINE INDUZIERTEN ERLEICHTERUNG VON SYNAPTISCHEN REAKTIONEN DURCH CHOLINESTERASE-INHIBITOREN RENFORCEMENT DE LA FACILITATION INDUITE PAR AMPAKINE DES REPONSES SYNAPTIQUES PAR LES INHIBITEURS DE LA CHOLINESTERASE (84) Designated Contracting States: (74) Representative: Baldock, Sharon Claire AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Boult Wade Tennant HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR Verulam Gardens 70 Gray’s Inn Road (30) Priority: 26.01.2004 US 539422 P London WC1X 8BT (GB) (43) Date of publication of application: (56) References cited: 02.11.2006 Bulletin 2006/44 EP-A- 1 203 584 US-A- 5 747 492 US-B2- 6 689 795 (73) Proprietors: • CORTEX PHARMACEUTICALS, INC. • JOHNSON STEVEN A ET AL: "Randomized, Irvine, CA 92618 (US) double-blind, placebo-controlled international • The Regents of The University of California clinical trial of the Ampakine CX516 in elderly Oakland, CA 94607-5200 (US) participants with mild cognitive impairment. -
Ampakine CX1942 Attenuates Opioid-Induced Respiratory Depression and Corrects the Hypoxaemic Effects of Etorphine in Immobilized Goats (Capra Hircus)
Ampakine CX1942 attenuates opioid-induced respiratory depression and corrects the hypoxaemic effects of etorphine in immobilized goats (Capra hircus) Anna J Haw*, Leith CR Meyer*,†, John J Greer‡ & Andrea Fuller*,† * Brain Function Research Group, Faculty of Health Sciences, School of Physiology, University of the Witwatersrand, Parktown, South Africa †Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa ‡Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada Correspondence: Anna J Haw, Brain Function Research Group, Faculty of Health Sciences, School of Physiology, University of the Witwatersrand, 7 York Road, Parktown 2193, South Africa. E-mail: [email protected] Abstract Objectives: To determine whether CX1942 reverses respiratory depression in etorphine- immobilized goats, and to compare its effects with those of doxapram hydrochloride. Study design: A prospective, crossover experimental trial conducted at 1753 m.a.s.l. Animals: Eight adult female Boer goats (Capra hircus) with a mean ± standard deviation mass of 27.1 ± 1.6 kg. Methods: Following immobilization with 0.1 mg kg−1 etorphine, goats received one of doxapram, CX1942 or sterile water intravenously, in random order in three trials. Respiratory rate, ventilation and tidal volume were measured continuously. Arterial blood samples for the determination of PaO2, PaCO2, pH and SaO2 were taken 2 minutes before and then at 5 minute intervals after drug administration for 25 minutes. Results: Doxapram corrected etorphine-induced respiratory depression but also led to arousal and hyperventilation at 2 minutes after its administration, as indicated by the low −1 PaCO2 (27.8 ± 4.5 mmHg) and ventilation of 5.32 ± 5.24 L minute above pre-immobilization values. -
(12) United States Patent (10) Patent No.: US 8,039,468 B2 Greer (45) Date of Patent: Oct
US008O39468B2 (12) United States Patent (10) Patent No.: US 8,039,468 B2 Greer (45) Date of Patent: Oct. 18, 2011 (54) METHOD OF INHIBITION OF Denavit-Saubie et al., “Effects of opiates and methionine-enkephalin RESPRATORY DEPRESSIONUSING on pontine and bulbar respiratory neurones of the cat.” 1978, Brain POSITIVE ALLOSTERICAMPARECEPTOR Res., 155(1):55-67. MODULATORS Feldman et al. “Looking for inspiration: new perspectives on respi ratory rhythm.”2006, Nat. Rev. Neurosci., 7(3):232-24. (75) Inventor: John Greer, Edmonton (CA) Funk, G.D., et al. "Generation and transmission of respiratory oscil lations in medullary slices: role of excitatory amino acids.” (1993).J. (73) Assignee: The Governors of the University of Neurophysiol. 70(4): 1497-1515. Funk, G.D., et al. “Modulation of neural network activity in vitro by Alberta, Edmonton, AB (CA) cyclothiazide, a drug that blocks desensitization of AMPA receptors' 1995, J. Neurosci., 15:4046-4056. (*) Notice: Subject to any disclaimer, the term of this Goff, D.C., et al. "A placebo-controlled pilot study of the ampakine patent is extended or adjusted under 35 CX516 added to clozapine in schizophrenia.” J. Clin. U.S.C. 154(b) by 996 days. Psychopharmacol., 21(5):484-487. Greer J.J., et al. “Role of excitatory amino acids in the generation and (21) Appl. No.: 11/847,835 transmission of respiratory drive in neonatal rat.” 1991, J. Physiol. 437: 727-749. (22) Filed: Aug. 30, 2007 Greer, J.J., et al. Respiratory and locomotor patterns generated in the fetal rat brain stem-spinal cordinvitro, J. Neurophysiol., 67:996-999. -
The Glutamate Receptor Ion Channels
0031-6997/99/5101-0007$03.00/0 PHARMACOLOGICAL REVIEWS Vol. 51, No. 1 Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. The Glutamate Receptor Ion Channels RAYMOND DINGLEDINE,1 KARIN BORGES, DEREK BOWIE, AND STEPHEN F. TRAYNELIS Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia This paper is available online at http://www.pharmrev.org I. Introduction ............................................................................. 8 II. Gene families ............................................................................ 9 III. Receptor structure ...................................................................... 10 A. Transmembrane topology ............................................................. 10 B. Subunit stoichiometry ................................................................ 10 C. Ligand-binding sites located in a hinged clamshell-like gorge............................. 13 IV. RNA modifications that promote molecular diversity ....................................... 15 A. Alternative splicing .................................................................. 15 B. Editing of AMPA and kainate receptors ................................................ 17 V. Post-translational modifications .......................................................... 18 A. Phosphorylation of AMPA and kainate receptors ........................................ 18 B. Serine/threonine phosphorylation of NMDA receptors .................................. -
Wo 2007/030697 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 15 March 2007 (15.03.2007) PCT WO 2007/030697 A2 (51) International Patent Classification: (US). PIRES, Jammieson, C. [US/US]; 5942 Alleghany A61K 31/16 (2006.01) A61K 38/15 (2006.01) Street, San Diego, CA 92139 (US). MORSE, Andrew A61K 31/4406 (2006.01) A61K 31/19 (2006.01) [US/US]; 10542 Rancho Carmel Drive, San Diego, CA (21) International Application Number: 92128 (US). GITNICK, Dana [CA/US]; 1524 Via Risa, PCT/US2006/034996 San Marcos, CA 92078 (US). TREUNER, Kai [DE/US]; 7665 Palmilla Drive, #5204, San Diego, CA 92122 (US). (22) International Filing Date: DEARIE, Alejandro, R. [US/US]; 555 Naples St., Apt. 7 September 2006 (07.09.2006) #307, Chula Vista, CA 9191 1 (US). (25) Filing Language: English (74) Agents: LAU, Kawai et al.; Townsend and Townsend and (26) Publication Language: English Crew LLP, 12730 High Bluff Drive, Suite 400, San Diego, (30) Priority Data: CA 92130 (US). 60/715,219 7 September 2005 (07.09.2005) US (81) Designated States (unless otherwise indicated, for every 60/764,963 3 February 2006 (03.02.2006) US kind of national protection available): AE, AG, AL, AM, 60/785,713 24 March 2006 (24.03.2006) US AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (71) Applicant (for all designated States except US): BRAIN- CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, CELLS, INC. -
Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by SZTE Publicatio Repozitórium - SZTE - Repository of Publications molecules Review Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions 1, 2,3, 4 1 Ferenc Zádor y,Gábor Nagy-Grócz y, Gabriella Kekesi , Szabolcs Dvorácskó , Edina Sz ˝ucs 1,5, Csaba Tömböly 1, Gyongyi Horvath 4,Sándor Benyhe 1 and László Vécsei 3,6,* 1 Institute of Biochemistry, Biological Research Center, Temesvári krt. 62., H-6726 Szeged, Hungary; [email protected] (F.Z.); [email protected] (S.D.); [email protected] (E.S.); [email protected] (C.T.); [email protected] (S.B.) 2 Faculty of Health Sciences and Social Studies, University of Szeged, Temesvári krt. 31., H-6726 Szeged, Hungary; [email protected] 3 Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Semmelweis u. 6., H-6725 Szeged, Hungary 4 Department of Physiology, Faculty of Medicine, University of Szeged, Dóm tér 10., H-6720 Szeged, Hungary; [email protected] (G.K.); [email protected] (G.H.) 5 Doctoral School of Theoretical Medicine, Faculty of Medicine, University of Szeged, Dóm tér 10., H-6720 Szeged, Hungary 6 Interdisciplinary Excellence Center, Department of Neurology, University of Szeged, Semmelweis u. 6., H-6725 Szeged, Hungary * Correspondence: [email protected]; Tel.: +36-62-545-351 These authors contributed equally to the work. y Academic Editor: Raffaele Capasso Received: 30 August 2019; Accepted: 14 October 2019; Published: 15 October 2019 Abstract: Schizophrenia, which affects around 1% of the world’s population, has been described as a complex set of symptoms triggered by multiple factors.